STOCK TITAN

Catheter Precision Partners With Two New German Heart Centers

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
partnership

Flyte Aviation (VJET) subsidiary Catheter Precision completed a clinical evaluation and its first commercial case in Germany at Klinikum Bayreuth.

A German distributor expanded its agreement beyond the LockeT suture retention device to include the VIVO mapping system and scheduled two fourth-quarter evaluations in Germany. In the commercial case, VIVO helped determine the catheter approach, identified two distinct abnormal heart rhythm patterns and reduced overall procedure time, with successful ablation and termination of multiple irregular rhythms. Catheter Precision aims to turn the initial evaluations into recurring commercial adoption.

Loading...
Loading translation...
5 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointGerman distributor agreement expanded beyond LockeT to include the VIVO mapping system.
  • Minor pointFirst German commercial case and a clinical evaluation completed at Klinikum Bayreuth.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Two fourth-quarter evaluations scheduled in Germany extend VIVO's clinical evaluation activity.
  • Minor pointCommercial case results included reduced procedure time, successful ablation and termination of multiple irregular rhythms.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Recurring commercial adoption is Catheter Precision's stated goal for the initial fourth-quarter evaluations.

Negative

  • None.

Key Figures

Arrhythmia morphologies identified: 2 distinct arrhythmia morphologies Scheduled evaluations: 2 evaluations
Arrhythmia morphologies identified
2 distinct arrhythmia morphologies
During Catheter Precision's first commercial case in Germany
Scheduled evaluations
2 evaluations
In Germany during the fourth quarter

Key Terms

arrhythmia, electrophysiology
2 terms
arrhythmia medical
"identified two distinct arrhythmia morphologies"
An arrhythmia is an irregularity in the heart’s normal rhythm, where the heartbeat is too fast, too slow, or uneven—like a drummer losing the beat and throwing off a song. It matters to investors because arrhythmias drive demand for drugs, medical devices, and tests; clinical trial results, regulatory approvals, safety alerts, or shifts in how common they are can quickly change a healthcare company's sales, costs, and stock outlook.
electrophysiology medical
"the gateway to ventricular therapies in electrophysiology"
The study and measurement of the electrical signals that control cells and tissues, most commonly used to diagnose and treat heart rhythm problems and to test how nerves and muscles communicate. Investors care because electrophysiology drives products, procedures and drugs—like monitoring systems, catheter tools and implants—that can alter a medical device or drug maker’s sales, regulatory approvals and clinical trial outcomes; think of it as checking and fixing the wiring that makes the body run.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

VIVO Addresses Critical Need in Ventricular Ablations by Determining Targets with "GPS" Accuracy

Initial Procedure Demonstrated Desired Outcomes with Successful Ablation and Termination of Multiple Irregular Rhythms

FORT MILL, S.C., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, a wholly owned subsidiary of Flyte Aviation, Inc. (NYSE American: VJET), today announced the successful completion of a clinical evaluation and its first commercial case in Germany at Klinikum Bayreuth.

Germany is the largest cardiology market in Europe and earlier this year, Catheter Precision partnered with a German distributor to expand its European footprint. After initially focusing on the company’s LockeT suture retention device, the distributor expanded its agreement to include the VIVO mapping system and scheduled two fourth-quarter evaluations in Germany.

Catheter Precision supported its first commercial procedure in the country, where VIVO demonstrated strong clinical value for the treating physicians. During the case, VIVO helped determine the optimal catheter approach, identified two distinct arrhythmia morphologies, and reduced overall procedure time while delivering successful patient outcomes.

“Completing our first commercial case in Germany at Klinikum Bayreuth is a major milestone that validates both the clinical impact of VIVO and our European expansion strategy,” said David Jenkins, CEO of Catheter Precision. “By helping physicians pinpoint distinct arrhythmia morphologies and significantly reduce procedure times, VIVO is proving its real-world value in the electrophysiology lab. As we convert these initial Q4 evaluations into recurring commercial adoption, we are building a scalable foundation for revenue growth and long-term shareholder value. We continue to believe that VIVO is the gateway to ventricular therapies in electrophysiology.”

About VIVO
Catheter Precision's VIVO™ (View Into Ventricular Onset) is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias prior to an electrophysiology procedure, potentially streamlining procedural workflow. VIVO has received marketing clearance from the U.S. FDA and carries the CE Mark.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. Catheter Precision is a wholly owned subsidiary of Flight Aviation, Inc., a NYSE/American listed company (VJET).

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding expected future growth, demand, strategic partnerships, market expansion, brand awareness, aircraft utilization and Flyte’s future operations, are forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially. Readers are encouraged to review the Company’s filings with the Securities and Exchange Commission, including its Forms 10-K and 10-Q, for a discussion of these risks.

Contact
IR@FlyFlyte.com
(800) 763-0904


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Where did Catheter Precision complete its first commercial VIVO case in Germany?

Catheter Precision completed its first commercial VIVO case in Germany at Klinikum Bayreuth. VIVO helped determine the catheter approach and identified two distinct abnormal heart rhythm patterns during the procedure.

Keep reading